
Unlocking longevity through in-situ Hematopoietic Stem Cell Rejuvenation using combined modulation of aging-disrupted pathways identified by publicly available and proprietary single-cell datasets from young and old human populations. Stem-cell exhaustion is a key hallmark of aging, contributing to impaired tissue repair, immune dysfunction, and systemic frailty. In this project, we took a novel approach to this challenge—rather than replacing aged blood-forming stem cells (HSCs) through transplantation, the project seeks to rejuvenate the body’s own stem cells in situ. We have analysed nearly 850,000 single-cell transcriptomes from healthy donors aged 23 to 91 from publically available and proprietary datasets, generating a high-resolution atlas of hematopoietic aging. The data reveal consistent age-related molecular signatures: younger HSCs show elevated expression of DNA repair and mitochondrial genes, while older cells exhibit ferroptosis drivers, inflammatory signaling (notably TNF and IL-17), and upregulation of CCR9 and long non-coding RNAs. These findings were confirmed in both circulating and bone marrow-derived HSCs, reinforcing their potential as biomarkers and intervention targets. In conclusion, we have identified a list of target genes, which can be used as a intervention for hematopoietic stem cell rejuvenation studies. The key insight is that we are targeting multiple aging mechanisms simultaneously - transcriptional stress responses, epigenetic regulation, and protein homeostasis. Classic damage repair thinking applied to the molecular level. This multi-pronged approach could achieve the robust rejuvenation that single interventions miss.
Unlocking longevity through in-situ Hematopoietic Stem Cell Rejuvenation using combined modulation of aging-disrupted pathways identified by publicly available and proprietary single-cell datasets from young and old human populations.
Stem-cell exhaustion is a key hallmark of aging, contributing to impaired tissue repair, immune dysfunction, and systemic frailty. In this project, we took a novel approach to this challenge—rather than replacing aged blood-forming stem cells (HSCs) through transplantation, the project seeks to rejuvenate the body’s own stem cells in situ. We have analysed nearly 850,000 single-cell transcriptomes from healthy donors aged 23 to 91 from publically available and proprietary datasets, generating a high-resolution atlas of hematopoietic aging. The data reveal consistent age-related molecular signatures: younger HSCs show elevated expression of DNA repair and mitochondrial genes, while older cells exhibit ferroptosis drivers, inflammatory signaling (notably TNF and IL-17), and upregulation of CCR9 and long non-coding RNAs. These findings were confirmed in both circulating and bone marrow-derived HSCs, reinforcing their potential as biomarkers and intervention targets. In conclusion, we have identified a list of target genes, which can be used as a intervention for hematopoietic stem cell rejuvenation studies. The key insight is that we are targeting multiple aging mechanisms simultaneously - transcriptional stress responses, epigenetic regulation, and protein homeostasis. Classic damage repair thinking applied to the molecular level. This multi-pronged approach could achieve the robust rejuvenation that single interventions miss.
Therapeutic Relevance
The proposed mechanism is scientifically plausible and well-grounded. HSC aging is a biologically validated driver of immune decline, anemia, and hematologic malignancies. The project targets well-characterized aging pathways (DNA damage, epigenetic drift, mitochondrial dysfunction, inflammatory signaling) identified through rigorous analysis of ~850,000 single-cell transcriptomes. The multi-modal approach targeting transcriptional stress responses, epigenetic regulation, and protein homeostasis simultaneously is scientifically sound. Key targets (NR4A1/2, CD38, UHRF1, CCR9) have published literature supporting their roles in HSC biology. However, the score is not a 5 because: (1) no experimental validation has been performed yet — all evidence is computational/bioinformatics; (2) the AubrAI-generated hypothesis, while interesting, remains unvalidated; and (3) the leap from differentially expressed genes to therapeutic targets requires functional proof that modulating these genes actually rejuvenates HSCs, which is still pending.
Therapeutic Optionality
The concept demonstrates strong therapeutic optionality. HSC rejuvenation could address multiple therapeutic areas: age-related immune decline (immunosenescence), anemia, myelodysplastic syndromes, leukemia prevention, chronic inflammation, and broader regenerative medicine applications. The multi-modal intervention framework (mRNA, siRNA, small molecules, CRISPR, gene therapy) provides flexibility in modality selection. The platform approach — using scRNA-seq and AI/ML to identify targets — is transferable to other stem cell types and aging contexts. Multiple drug repurposing opportunities exist (e.g., cromolyn sodium for TPSB2/TPSAB1, fasudil for RhoA). The concept could extend to organ-on-a-chip and in vivo nanoparticle delivery platforms. A score of 5 is not warranted because the optionality remains theoretical at this stage, and the primary focus is narrowly on HSCs without demonstrated cross-tissue applicability yet.
Intellectual Property
The IP position is moderate. Strengths: the specific combination of targets identified through proprietary computational analysis and the multi-modal temporal coordination strategy could be patentable as a novel therapeutic approach. The use of proprietary datasets alongside public data adds some differentiation. The specific gene target combinations and intervention protocols (phased mRNA/siRNA/small molecule delivery) may constitute novel compositions or methods. However, significant concerns exist: (1) many individual targets (CD38, RhoA, NR4A, rapamycin/mTOR) are well-known in the aging and HSC literature, creating prior art risks; (2) no patents have been filed yet, leaving the IP unprotected; (3) several proposed small molecules (fasudil, rapamycin, cromolyn sodium) are existing drugs with established IP landscapes; (4) the computational methodology (scRNA-seq + GRN analysis) is widely used, limiting method-based IP; (5) specific gene names and combinations are not disclosed in the documents reviewed, making it difficult to fully assess novelty. The competitive landscape in HSC rejuvenation and aging is active, with multiple academic and commercial groups pursuing similar approaches.